SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

Article citations

More>>

D. Situ, H. Long, P. Lin, Z. Zhu, J. Wang, X. Zhang, Z. Xie and T. Rong, “Expression and Prognostic Relevance of CD44v6 in Stage I Non-Small Cell Lung Carcinoma,” Journal of Cancer Research and Clinic Oncology, Vol. 136, No. 8, 2010, pp. 1213-1219. doi:10.1007/s00432-010-0771-5

has been cited by the following article:

  • TITLE: Study of the Peripheral Blood CD44 Expression in the Patients with Non-Small Cell Lung Cancer

    AUTHORS: Dong-Ping Jiang, Jun Yang, Hui-Feng Yuan, Yu-Quan Wu, Pei-Yong Qiu, Guang-Zhou Lu, Qing-Yong Chen

    KEYWORDS: CD44 Expression, Non-Small Cell Lung Cancer, Peripheral Blood, Treatment

    JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.5, December 31, 2011

    ABSTRACT: Previous study has demonstrated that the peripheral blood CD44 expression level is related with the clinical stage and lymph node metastasis of lung cancer. The present comment was to investigate the relationship between the peripheral blood CD44 expression level and clinic pathological change in 50 patients with non-small cell lung cancer (NSCLC) by flow cytometry method. The results showed that 1) the peripheral blood CD44 expression level in the NSCLC group was higher than that in the benign group (467 ± 15) or the normal group (448 ± 15); 2) operation decreased the peripheral blood CD44 expression level in the NSCLC group (533 ± 10 vs. 324 ± 11); 3) it also showed same results in NSCLC patients with and without lymph node metastasis (559 ± 12 vs. 477 ± 15) or before and after chemotherapy (550 ± 13 vs. 372 ± 10); 4) there were significant differences in the peripheral blood CD44 expression level in non-small cell lung cancer patients of the clinical stage I, II, III and IV (474 ± 14, 526 ± 12, 528 ± 16 and 599 ± 20); And the peripheral blood CD44 expression level was not associated with the clinical pathology parameter including the patient age, gender and tumor size. The data suggested that the peripheral blood CD44 expression level was related with the NSCLC progress, lymphatic metastasis and clinical treatment, and the peripheral blood CD44 expression level as the clinical regular examination should evaluate the progress, lymphatic metastasis and clinical treatment for the patients with NSCLC.